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Abstract
Glioblastoma multiforme is the most aggressive brain tumor, and human T98G cells constitute a useful glioblastoma multi-
forme model to evaluate the chemotherapeutic agents. Modern life (shiftwork, jetlag, etc.) may cause circadian disorgani-
zation promoting higher cancer risk and metabolic disorders. Although little is known about the tumor-intrinsic circadian
clock function, pharmacological modulation of circadian components may offer selective anticancer strategies. REV-ERBs are
heme-binding circadian clock components acting as repressors of processes involved in tumorigenesis such as metabolism,
proliferation, and inflammation. A synthetic pyrrole derivative (SR9009) that acts as REV-ERBs-specific agonists exhibits
potent in vivo activity on metabolism and tumor cell viability. Here, we investigated SR9009 effects on T98G cell viability,
differential chemotherapy time responses, and underlying metabolic processes (reactive oxygen species [ROS] and lipid
droplets [LDs]) and compared it with the proteasome inhibitor Bortezomib treatment. SR9009-treated cells exhibited
significant reduction in cell viability with consequences on cell cycle progression. Dexamethasone synchronized cells dis-
played differential time responses to SR9009 treatment with highest responses 18 to 30 h after synchronization. SR9009
treatment decreased ROS levels while Bortezomib increased them. However, both treatments significantly increased LD
levels, whereas the combined treatment showed additive or synergistic effects between both drugs. In addition, we extended
these studies to HepG2 cells which also showed a significant decrease in cell viability and ROS levels and the increase in LD
levels after SR9009 treatment. Our results suggest that the pharmacological modulation of the tumor-intrinsic clock by
REV-ERB agonists severely affects cell metabolism and promotes cytotoxic effects on cancer cells.
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Introduction
Carcinogenesis is a complex and multi-etiological process
resulting in the accumulation of genetic alterations pri-
marily in genes involved in the regulation of signaling
pathways relevant to the control of cell growth and divi-
sion (reviewed in Hanahan and Weinberg, 2011).
Neoplastic processes include a number of typical charac-
teristics such as sustained proliferative activation, growth
suppressor evasion, cell death resistance, replicative
immortality, induction of angiogenesis, and invasiveness
and metastasis, all of which are based on genome insta-
bility and inflammation.
Under physiological conditions, circadian clocks are
near 24-h endogenous oscillators that control a complex
net of physiological and behavioral processes such as the
daily sleep and wake cycle, body temperature, feeding
behavior, hormone secretion, drug and xenobiotic
metabolism, glucose homeostasis, and cell cycle progres-
sion (Lowrey and Takahashi, 2004; Bell-Pedersen et al.,
2005). At the cellular level, a redox/metabolic oscillator
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(R/MO) has been described to interact with the circadian
molecular clock (Dibner and Schibler, 2015; Wagner
et al., 2018); this R/MO has been shown to be ancestral
and highly conserved through evolution (review in Edgar
et al., 2012). Taken together, we may infer that the cel-
lular clock that temporarily controls cellular processes is
made up of a molecular clock (transcription/translation
feedback loop) and an R/MO. In mammals, disruption
of circadian rhythms increases cancer incidence and met-
abolic disorders. Cell-autonomous clocks are composed
of a transcription–translation-based feedback loop made
up of a set of genes that include Clock (and its paralogue
Npas2) and Bmal1 as activator components and Per1,
Per2, Cry1, and Cry2 as repressor components.(King
et al., 1997; Gekakis et al., 1998). The entire cycle of
transcription and translation takes approximately 24
h to be completed. In addition, the CLOCK–BMAL1
complex may activate a second alternative cycle involving
the nuclear receptors REV-ERBa and REV-ERBb which
compete at the retinoic acid-related orphan receptor
(ROR)-binding elements with the activators RORa,
RORb, and RORc (Preitner et al., 2002; Sato et al.,
2004; Zhang et al., 2015). The rhythmic expression of
REV-ERBa/b leads to the repression of BMAL1 and
CLOCK, which in turn induces a rhythm in these genes
that is in antiphase with period (PER) expression
rhythms (Preitner et al., 2002). In fact, REV-ERBs and
RORs are crucial components of the circadian clock that
links the core circadian oscillator to the regulation of
clock-controlled genes, which in turn regulate metabolic
pathways and several physiological processes, including
metabolism, development, and immunity. In conse-
quence, loss-of-function studies both in vitro and in vivo
support the REV-ERB key role in lipid metabolism, reg-
ulation of plasma glucose levels (Delezie et al., 2012; Solt
et al., 2012), as well as the oxidative capacity of skeletal
muscle and mitochondrial biogenesis (Woldt et al., 2013).
The development and characterization of pyrrole
derivatives SR9009 and SR9011 (Solt et al., 2012) as
specific REV-ERB agonists opened up the possibility of
targeting these receptors to treat several circadian disor-
ders, including metabolic diseases (obesity, dyslipidemia,
and glucose intolerance; Green et al., 2008; Bass and
Takahashi, 2010; Bass, 2012; Eckel-Mahan and
Sassone-Corsi, 2013; Gamble and Young, 2013), sleep
disorders (Solt et al., 2012) and cancer (Sulli et al.,
2018). Indeed, pharmacological modulation of circadian
rhythms by these agonists affects tumor cell viability by
restraining pathways that are aberrantly activated in
cancer (Sulli et al., 2018). Consistent with the range of
metabolic effects noted in REV-ERBa-null mice, phar-
macological activation of REV-ERB with SR9009 and
SR9011 had additional metabolic effects in mice includ-
ing weight loss in diet-induced obese mice, events associ-
ated with an increase in energy expenditure without
alterations in locomotor behavior or food intake (Solt
et al., 2012). Taking into account the role of
REV-ERBs on lipid, glucose, and energetic metabolism
regulation and the high metabolic demands of cancer
cells, we postulated that a pharmacological modulation
of circadian components repressors such as REV-ERBs
could alter metabolic pathways that compromise cancer
cell survival.
Although disruption of the biological clock altering
metabolic pathways can lead to diverse pathologies,
little is known about the temporal regulation of cellular
metabolism in tumor cells. Glioblastoma multiforme
(GBM) is the most aggressive human brain tumor
characterized by the aberrant proliferation growth of
glial-like tumor cells. In this connection, the human glio-
blastoma T98G cells constitute an appropriate cancer cell
model to investigate the tumor-intrinsic circadian clock.
In our previous work, we found that proliferating T98G
cells contain a functional intrinsic oscillator that controls
diverse metabolic processes including lipid metabolism,
levels of reactive oxygen species (ROS), peroxiredoxin
oxidation cycles and susceptibility to treatment with
the proteasome inhibitor Bortezomib (BOR; Wagner
et al., 2018).
Here, we investigated the effects of SR9009 treatment
in T98G cell cultures and compared it with BOR treat-
ment assessing cell viability, differential time responses to
chemotherapy after synchronization with dexamethasone
(DEX), and metabolic processes involving ROS and lipid
droplet (LD) levels. In addition, we extended these stud-
ies to HepG2 cells, a nonneuronal tumor cell line derived
from human liver hepatocellular carcinoma.
Material and Methods
Cell Cultures
T98G cells are derived from the human GBM (ATCC,
Cat. No. CRl-1690, RRUD: CVCL0556, Manassas, VA,
USA) and tested positive for glial cell markers and neg-
ative for mycoplasma contamination. HepG2 cells
(ATCC, Cat. No. HB-8065, RRID: CVCL0027) are
derived from the human hepatocellular carcinoma.
Both cell lines were grown in Dulbecco’s modified
Eagles medium (DMEM) (Gibco, BRL, Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS) according to (Portal et al., 2007) at
37C and 5% CO2.
SR9009 Treatment and Determination of Cell
Viability by MTT Assay
Cells were plated in 96-well plates at a density of 1 104
and were allowed to attach overnight at 37C. Cultured
cells were incubated with DMSO (vehicle) or REV-ERB
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agonist (SR9009) at different concentrations (10, 20, and
40 mM) and incubation time (24, 48, and 72 h). Stock
solutions of SR9009 were resuspended in DMSO to a
final concentration of 50 mM (stock solution) according
to manufacturer’s instructions. After incubation, 10 mL
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reagent (5 mg/mL; Sigma) were added
to each well, and plates were further incubated for 2 h at
37C as described (Vlachostergios et al., 2013). Then,
100 mL of DMSO:isopropanol (1:1, v/v) was added to
each well followed by incubation for a fewminutes at
room temperature protected from light. Samples were
analyzed at a wavelength of 570 nm with a reference at
650 nm in an Epoch Microplate Spectrophotometer.
Vehicle-treated cells (DMSO) were considered as 100%
of viability.
In other series of experiments, 5 103 HepG2 cells
were allowed to attach overnight at 37C in a 96-well
plate. Cultured cells were incubated with DMSO
(vehicle) or REV-ERB agonist (SR9009) at different con-
centrations (5, 10, 20, and 40 mM) for 96 h. Then, cell
viability was analyzed by MTT assay considering
vehicle-treated cells (DMSO) as 100% of viability.
SR9009 Treatment of T98G Cells and Determination
of Cell Viability by alamarBlue Assay
Cells were plated in 96-well plates at the density of
1.5 103 and allowed to attach overnight at 37C.
Cultured cells were incubated with DMSO (vehicle)
or REV-ERB agonist (SR9009) at final concentration
of 20 mM for 48 or 72 h. After incubation, 10 mL of
alamarBlue reagent (Invitrogen) were added to each
well (final volume: 100 mL in 96-well plates) and plates
were further incubated for 3 h at 37C protected from
light. Fluorescence intensity was analyzed at an excita-
tion wavelength of 540 to 570 nm, and fluorescence emis-
sion reads at 580 to 610 nm in a Biotek microplate reader.
Vehicle-treated cells (DMSO) were considered as 100%
of viability.
Differential Temporal Susceptibility to SR9009
or BOR Treatment
T98G cells were plated in 96-well plates at the density of
1 104 and allowed to attach overnight in a CO2 incu-
bator at 37C. Cell cultures were synchronized by a
20-min shock with 100 nM DEX and were treated with
SR9009 (20 mM 48h) or BOR (500 nM 36 h; Comba
et al., 2019) at different times postsynchronization.
After incubation, cell viability was determined by
MTT assay as described earlier and analyzed at 570 nm
with a reference at 650 nm in an Epoch Microplate
Spectrophotometer. Vehicle-treated cells (DMSO) were
considered as 100% of viability.
Combined Chemotherapeutic Treatments on
T98G Cells
In other series of experiment, T98G cells were treated
with both drugs together to evaluate the additive/syner-
gistic effect between them. For this, T98G cells were syn-
chronized by a 20min shock with 100 nM DEX at 37C
and maintained in 5% FBS-DMEM. Cells were treated
with different drug concentrations alone or in combina-
tion as follows: BOR (50 or 500 nM), SR9009 (10 or
20 mM), BOR (50 nM)þ SR9009 (10mM), or BOR
(500 nM)þ SR9009 (20 mM), 18 h postsynchronization,
and were incubated for 36 h at 37C. Cell viability was
analyzed by MTT assay as described earlier. Vehicle-
treated cells (DMSO) were considered as 100% of
viability.
Cell Cycle Progression Analysis in SR9009-Treated
T98G Cells
T98G cells incubated with DMSO (vehicle) or SR9009
(20mM) were arrested in serum-free DMEM for 36 h.
Then, the medium was removed and either vehicle or
SR9009-treated cells were stimulated with 20% serum
for 16 h in the presence of DMSO or SR9009, respective-
ly. Finally, cells harvested by trypsinization were washed
in cold phosphate buffered saline (PBS) and fixed with
cold 70% ethanol at 20C for at least 24 h. Cell pellets
were resuspended in 150 mL of staining solution
(PBS containing 50 mg/mL propidium iodide and 10 mg
RNAse A) as reported (Acosta-Rodrıguez et al., 2013).
Cell cycle analysis was performed by a flow cytometer
running at least 50,000 cells. The analysis program used
was FlowJo software (Verity Software House, Topsham,
ME, USA).
Redox State in SR9009-Treated Cells
Redox state was analyzed in T98G cells incubated with
SR9009 (20 mM, 48 h) or BOR (500 nM, 24 h) and in
SR9009-treated-HepG2 cells (40mM, 48 h). Briefly, the
culture medium was removed and cells were washed
with cold PBS 1X and harvested by trypsinization.
Then, cells were incubated with 2,7-dichlorodihydro-
fluorescein diacetate at 2 mM final concentration for
40min at 37C, washed twice with PBS 1X, and the fluo-
rescence intensity was measured by flow cytometry at
530 nm when the sample was excited at 485 nm
(Eruslanov and Kusmartsev, 2010). Cells without the
fluorescent indicator were used as negative control, and
propidium iodide (50 mg/mL) staining was used to dis-
criminate viable cells. FlowJo software was used to ana-
lyze fluorescence intensity (Verity Software House).
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Determination of LDs on Cells Treated With
SR9009 or BOR
T98G cells were incubated with SR9009 (20 mM, 48 h) or
BOR (500 nM, 24 h), and LD levels were analyzed by
confocal microscopy and flow cytometry. For microsco-
py visualization, cultured cells were fixed for 15min in
4% paraformaldehyde in PBS and washed twice with
PBS 1X. Then, cells were incubated with Nile Red
(1mg/mL, Sigma, Tokyo, Japan) for 15min at room tem-
perature protected from light. Coverslips were finally
washed thoroughly and visualized by confocal microsco-
py (FV1200; Olympus, Tokyo, Japan). Cellular
nuclei were visualized by 40,6-diamidino-2-phenylindole
(DAPI) staining. Average size quantification of LD was
carried out with ImageJ software.
For flow cytometry analysis, either control or treated
cells were harvested by trypsinization and washed twice
with PBS 1X. Cell pellets were resuspended in 200 mL of
PBS containing 1mg/mL Nile Red and were incubated for
15min at room temperature protected from light. Then,
cells were washed twice with PBS 1X, and the fluores-
cence intensity was measured by flow cytometry (BD
LSRFortessaTM cell analyzer) with 575/26 filter. A neg-
ative control including cells without the fluorescent indi-
cator was used. FlowJo software was used to analyze
fluorescence intensity.
HepG2 cells were treated with SR9009 (10 or 40 mM,
96 h), and LD content was assessed by Nile Red
(1mg/mL) staining as described earlier. Average size
and area of LDs were performed by the ImageJ software.
Cellular nuclei were visualized by DAPI staining.
Immunocytochemistry
Immunocytochemistry was performed as described
(Morera et al., 2016). Briefly, cultured cells were fixed
for 15min in 4% paraformaldehyde in PBS and 10min
in methanol. Coverslips were washed in PBS, were
treated with blocking buffer (PBS supplemented with
0.1% bovine serum albumin, 0.1% Tween 20, and
0.1% glycine) and were incubated overnight with prima-
ry antibodies (Table 1) at 4C. Coverslips were washed 3
times and were incubated with goat antirabbit immuno-
globulin G (IgG; Jackson 549 antibody 1:1,000) or goat
antimouse IgG (Jackson 488 antibody 1:1,000) for 1 h at
room temperature. Coverslips were finally washed thor-
oughly and visualized by confocal microscopy (FV1200;
Olympus). Cellular nuclei were visualized by DAPI
staining.
Statistics
Statistical analyses involved a one- or two-way analysis
of variance (ANOVA) to test the time or drug treatment
effects and Kruskal–Wallis (K-W), the nonparametric
one-way ANOVA or Scheirer–Ray–Hare test when the
normality assumption of residuals was violated. Pairwise
comparisons involved the Student t test, Bonferroni, or
Dunn–Bonferroni post hoc when appropriate as stated in
figure legends. For Scheirer–Ray–Hare test, all analyses
were followed by K-W test with Bonferroni correction as
post hoc analysis. Data are expressed as mean standard
error of the mean. In all cases, significance was consid-
ered at p< .05.
Results
Here, we investigated SR9009 effects and compared it
with BOR, a proteasome inhibitor previously used, on
T98G cell viability, differential chemotherapy time
responses, and underlying metabolic processes concern-
ing ROS and LD levels. Also, we extended these studies
to HepG2 cells to evaluate the SR9009 effects on cell
viability, LD, and ROS levels.
Characterization of T98G Cells and Susceptibility to
SR9009 Treatment
Human T98G cells kept in culture under proliferative
conditions (5% FBS-DMEM) expressed typical markers
for glial cells such as vimentin, glutamine synthase, and
glial fibrillary acidic protein (Figure 1(a) to (c)) as well as
the circadian clock component REV-ERBa (Figure 1(d)).
In addition, T98G cells were previously shown to express
the clock protein PER1 and display temporal fluctuations
on PER1-like protein by immunocytochemistry with
highest levels at 18 and 24 h after synchronization
(Wagner et al., 2018).
When cells were treated with the REV-ERB-specific
agonist SR9009 at different concentrations going from
10 to 40 mM for 24, 48, or 72 h (Figures 1 and 2(a)),
Table 1. Antibody List.
Antibody Host Catalogue Dilution
Glutamine synthase Mouse Millipore Cat# MAB302, RID:AB_2110656 1:100
Vimentin Mouse Sigma-Aldrich Cat# V5255, RRID:AB_477625 1:750
GFAP Rabbit Agilent Cat# Z0334, RRID:AB_10013382 1:250
REV-ERBa Mouse Santa Cruz Biotechnology Cat# sc-100910, RRID:AB_2154647 1:100
Note. Summary of antibodies used indicating antibody name, host, catalogue number, and dilution for immunochemistry. GFAP¼ glial fibrillary acidic protein.
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significant effects on cell morphology (Figure 1(e)
and (f)) and reduction in cell viability were observed at
final concentrations of 20 and 40 mM for 48 and 72 h
(Figure 2(a)) as compared with vehicle-treated controls
(p< .0001 by K-W). It is noteworthy that a significant
decrease in cell viability is observed after SR9009 treat-
ment with only approximately 20% of cells remaining
viable under the tested conditions (20 and 40 mM of
SR9009 for 72 h). Moreover, a significant reduction in
cell viability was also observed on SR9009-treated
HepG2 cells (40 mM for 96 h; p< .0002 by K-W;
Figure 2(b)). Nevertheless, although hepatic tumor cells
seemed to be more resistant to chemotherapy because
higher drug concentrations and longer treatment dura-
tions were required to cause less than 25% of cell survival
(40mM for 96 h), we cannot discard any significant drug
effect in cell viability at earlier times in combination with
a higher drug concentration.
In addition, to further support these observations, cell
viability was also analyzed by alamarBlue assay after
T98G cells incubation with SR9009 (20 mM) for 48 or
72 h at 37C. Similar to findings found for MTT assay,
Figure 1. Protein expression in T98G cells by immunocytochemistry and SR9009 treatment effect. T98G cells express typical markers of
glial cells such as vimentin (a—green) and GS (b—green) visualized by immunofluorescence with specific primary antibodies and confocal
microscopy. T98G cells were incubated with vehicle (DMSO) or SR9009 (20 mM) for 48 h and immunolabeled for GFAP (c and e—red) or
REV-ERBa (d and f—green) with specific primary antibodies and confocal microscopy; insets on the right further magnified a single cell in
both conditions (DMSO and SR9009 treatment). See “Materials and Methods” section for further detail. Scale bar¼ 10 mm. GFAP¼ glial
fibrillary acidic protein; GS¼ glutamine synthase.
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a significant reduction in cell viability was observed when
cells were treated with SR9009 (20mM) for 48 or 72 h
(p< .0005 by ANOVA; Supplementary Figure 1).
Differential Temporal Susceptibility to SR9009
Treatment
T98G cells were synchronized with DEX (100 nM) and
were treated with SR9009 (20 mM) for 48 h at different
times postsynchronization along 36 h. Cell viability was
analyzed by MTT assay in SR9009-treated cells, and
showed a significant temporal effect of drug treatment,
with the lowest levels of viability during a time window
going from 18 to 30 h after synchronization. The statis-
tical analysis clearly revealed a significant effect of treat-
ment versus time (p< .0041 by K-W; Figure 3(a)). These
observations agree with those previously found in syn-
chronized T98G cells treated with BOR (500 nM) for 36 h
(Wagner et al., 2018) exhibiting the lowest cell viability in
a time window going from 12 to 24 h postsynchronization
(p< .0007 by K-W; Figure 3(b)).
Effects of Cell Cycle Progression of SR9009 Treatment
on T98G Cells
To further investigate whether SR9009 treatment alters
cell cycle progression, T98G cells were arrested in serum-
free medium for 36 h in the presence of DMSO (vehicle)
or SR9009 (20 mM). Then, medium was removed and
either control or treated cells were stimulated with 20%
serum for 16 h in the presence of DMSO or SR9009
respectively. Flow cytometry analysis showed a higher
proportion of SR9009-treated cells (58%) in G0/G1
phases after serum stimulation as compared with
vehicle-treated cells (43%; p< .0053 by t test). By con-
trast, vehicle-treated cells showed a higher proportion of
cells in S phase (40%) with respect to SR9009-treated
cells (22%; p< .0121 by t test; Figure 4(a) to (c)).
SR9009 Effect on Redox and Lipid Metabolism
To investigate whether oxidative stress could be involved
in the effects of SR9009 treatment in cell viability, we
analyzed ROS levels and compared it with those in
BOR-treated cells. To this end, T98G cells were incubat-
ed with SR9009 (20 mM) for 48 h, and the redox state was
analyzed by incubation with 20,70-dichlorodihydrofluor-
escein diacetate (2mM) for 40min at 37C. When fluores-
cence intensity was measured by flow cytometry, a
significant reduction in ROS levels was seen in SR9009-
treated cells as compared with vehicle-treated controls
(p< .007 by t test; Figure 5(a)). In contrast, T98G cells
previously incubated with BOR (500 nM) for 24 h
showed higher levels of ROS with respect to those in
control cells (p< .04 by t test; Figure 5(b)). Moreover,
SR9009 (40mM) treatment in HepG2 cells for 96 h also
showed a significant decreased on ROS levels as com-
pared with vehicle-treated cells (p< .0001 by ANOVA;
Figure 7(f)).
Figure 5.
In other series of experiments, we proceeded to eval-
uate the LD levels after treatments with SR9009 or BOR.
LDs are cytoplasmic organelles responsible for storing
the excess of cellular lipids (Farese and Walther, 2009;
Figure 2. Cell susceptibility to SR9009 treatment in cultures of T98G (a) and HepG2 (b) cells. (a) T98G cells were treated with different
SR9009 concentrations (10, 20, and 40 mM) for 24, 48, or 72 h at 37C. Cell viability that was analyzed by MTTassay revealed a significant
effect of SR9009 concentration (p< .001) and duration of treatment (p< .05) but not of interaction by Scheirer–Ray–Hare test. Post hoc
comparisons revealed that viability of T98G cells incubated with a final concentration of 10 mM of SR9009 differed from values of cells
treated with 20 or 40mM (**p< .017) while 24 h of treatment differed from those at 48 h or 72 h (**p< .017). The results are mean
 standard error of the mean of two independent experiments (n¼ 5–6/group). (b) HepG2 cells were treated with different SR9009
concentrations (5, 10, 20, and 40 mM) for 96 h. A significant reduction in cell viability was observed when HepG2 cells were treated with
40 mM for 96 h as compared with untreated cells (***p< .0002 by K-W). The results are mean standard error of the mean of two
independent experiments (n¼ 5–6/group).
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Beller et al., 2010; Brasaemle and Wolins, 2012) and
mainly involved in energy storage.
To investigate whether SR9009 treatment alters lipid
accumulation in LDs, we used Nile Red which is intense-
ly fluorescent and can serve as a sensitive vital stain for
the detection of cytoplasmic LDs. To this end, SR9009 or
BOR-treated cells were stained with Nile Red and LDs
visualized by confocal microscopy and flow cytometry.
First, LDs in SR9009-treated cells showed a higher aver-
age size as compared with vehicle-treated cells (p< .003
by t test; Figure 6(a) to (c)). In agreement with this, a
higher fluorescence intensity was visualized by flow
cytometry either in SR9009 or BOR-treated cells as com-
pared with untreated cells (p< .002 and p< .025, respec-
tively, by t test; Figure 6(d) to (f)).
Similar results were observed in HepG2 cells exhibit-
ing a higher average size of LDs after SR9009 treatment
(10 and 40 mM, 96 h) as compared with control cells
(p< .0001 by ANOVA; Figure 7(a) to (d)). Moreover,
the percentage of LD area related to the total area of
each cell was increased after drug treatment (40 mM, 96
h; Figure 7(e); p< .0001 by K-W).
Combined Chemotherapeutic Treatments on
T98G Cells
Even though SR9009 or BOR treatments showed marked
effects in cell viability, we explored whether the combi-
nation of these two drugs could improve chemotherapeu-
tic effects. To this end, T98G cells were treated with BOR
(50 or 500 nM), SR9009 (10 or 20mM), and their
combination (BOR 50 nMþSR9009 10 mM or BOR
500 nMþ SR9009 20 mM) at 18 h postsynchronization
for 36 h, and cell viability was analyzed by MTT assay.
When BOR or SR9009 treatments were given alone at
low doses, a 60% of cells still remained viable; however,
the combination of these compounds at low concentra-
tions (BOR 50 nMþSR9009 10 mM) reduced cell viabil-
ity to 28% (Figure 8(a)) as compared with each drug
alone (p< .003 by K-W). In addition, at high drug con-
centration, 28% and 34% of cells remained viable, after
BOR or SR9009 treatment, respectively; whereas, when
both drugs were applied together to T98G cells at high
doses, a significant reduction in cell viability was
observed and only 17% of cells were still viable
(p< .0001 by ANOVA; Figure 8(b)). The results clearly
demonstrated an important additive or synergistic effect
of drug combination.
Discussion
Our results demonstrated that the pharmacological mod-
ulation of tumor-intrinsic clock components by a specific
REV-ERB agonist severely affected tumor cell metabo-
lism and promoted cytotoxic effects on glioma and hepa-
tocellular carcinoma cells. These observations showed for
the first time that glioblastoma cells can be treated phar-
macologically under a time-dependent therapy through
the modulation of particular circadian clock components
such as REV-ERBs involving the control of metabolism
to achieve the highest antitumor treatment efficacy.
SR9009 treatment altered the typical glial cell
Figure 3. Temporal response to SR9009 (a) or BOR (b) treatment in T98G cells. (a) Cells were synchronized with DEX (100 nM), and
SR9009 was added to a final concentration of 20 mM at different times postsynchronization for 48 h. Cell viability was analyzed by MTT
assay as described in “Materials and Methods” section. A significant temporal variation was observed in levels of T98G cell viability
(p< .004 by K-W). Pairwise comparisons by Dunn–Bonferroni post hoc revealed that the treatment beginning at 6 h post synchronization
significantly differed from those starting at 18, 24, and 30 h after synchronization. The results are mean standard error of the mean of
three independent experiments (n¼ 5–6/group). (b) DEX-synchronized cells were treated with BOR (500 nM) for 36 h at different times
postsynchronization and cell viability assessed by MTTassay. A significant time effect was observed in levels of T98G cell viability (p< .0007
by K-W) as previously observed in Wagner et al. (2018). Results are mean standard error of the mean from one representative
experiment (n¼ 5–6/group). BOR¼ Bortezomib.
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morphology (Figure 1), cell viability (Figures 2 and 3),
and metabolism by increasing levels of LDs and decreas-
ing those for ROS (Figures 5 and 6). Moreover, the treat-
ment with SR9009 further potentiates the effect of BOR
(Figure 8), which was previously shown to have strong
effects on cell viability of glioma cells under a circadian
chronotherapy (Wagner et al., 2018). However, the mech-
anisms used for these two chemotherapeutic agents
seemed to be different in terms that BOR inhibits the
proteasome function while SR9009 acts on the clock-
related cellular metabolism; nevertheless, both of them
were shown to substantially elevate levels of LDs
(Figures 6 and 7). Also, and remarkably, both agents
exhibited a clear time window of highest cellular suscep-
tibility to treatment with maximal effects from 12–18 to
24 h after DEX synchronization (Figure 3 and Wagner
et al., 2018). Moreover, when the circadian clock was
disturbed by Bmal1 knock-down, a circadian variation
in BOR treatment susceptibility was still observed but
with a different phase and amplitude than that described
in wild-type T98G cells (Wagner et al., 2018). In previous
reports, proliferative T98G cells were synchronized by
DEX which is commonly used in GBM patients to
reduce inflammation or as a chemotherapy adjuvant; in
Figure 4. Effects of SR9009 treatment on cell cycle distribution of T98G cells. T98G cells incubated with DMSO (vehicle) or SR9009 (20
mM) were arrested in serum-free DMEM for 36 h. Then, the medium was removed and either vehicle or treated cells were stimulated with
20% fetal bovine serum for 16 h in the presence of DMSO or SR9009 as appropriate. Cell cycle phases were analyzed by staining with
propidium iodide and flow cytometry. Representative cell cycle distributions are shown in control (a) or SR9009-treated cells (b). (c)
Quantification of the percentage of cells in each phase showed a higher proportion of SR9009-treated T98G cells in G0–G1 phase (G0–G1
*p< .0053, S *p< .01 by t test). The results are mean standard error of the mean of three independent experiments (n¼ 4/group).
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fact, glucocorticoids can inhibit cancer cell proliferation
by limiting the number of cells in S phase and addition-
ally increasing the time spent in the G1 phase (Kiessling
et al., 2017; Wagner et al., 2018).
Results shown in Figure 4 strongly indicate that this
REV-ERB agonist also affected the cell cycle progression
because approximately 60% of SR9009-treated cells
remained arrested in G0/G1 phases as compared with con-
trol cells after serum stimulation. It is known that GBM
is the most aggressive brain tumor and that the develop-
ment of more effective anticancer strategies can be useful
for clinical use. In this regard, the combination of both
agents applied at the right temporal window and at lower
individual doses as seen in glioma cell cultures can offer
an additional opportunity to effectively treat cancer cells
in a synergic manner.
Circadian rhythms are intricately linked to the regula-
tion of metabolism, and genetic perturbations of core
clock genes lead to a range of abnormal metabolic phe-
notypes in mice, including obesity, dyslipidemia, and glu-
cose intolerance (Green et al., 2008; Bass and Takahashi,
2010; Bass, 2012; Eckel-Mahan and Sassone-Corsi, 2013;
Gamble and Young, 2013). In this connection, modern
life including hypercaloric diets, sedentary routines, arti-
ficial illumination at night, the reduction in sleep hours,
shiftwork, and jetlag among others may cause circadian
disorganization promoting higher cancer risk and meta-
bolic disorders.
RORs and REV-ERBs play key roles in the regula-
tion of metabolic pathways linking the core circadian
oscillator to the regulation of clock-controlled genes.
Loss-of-function studies both in vitro and in vivo dem-
onstrate that REV-ERBs have a crucial role in lipid
metabolism as seen in REV-ERBa-null mice exhibiting
dyslipidemia with elevated levels of very-low-density
lipoprotein, triglyceride, and increased serum levels of
apolipoprotein C3 (Raspe et al., 2001, 2002). In this
connection, lipids are stored in LDs as neutral lipids,
namely, free fatty acids and cholesterols that are enzy-
matically converted to triacylglycerol and cholesteryl
esters, respectively, and then incorporated into LDs
(Farese and Walther, 2009; Beller et al., 2010;
Brasaemle and Wolins, 2012). These organelles are
not only restricted to energy storage but also partici-
pate in stress protection, protein sequestration, mem-
brane trafficking, and signaling having a great impact
on physiology, health, and disease (Welte and Gould,
2017). Nevertheless, the treatment with SR9009 signif-
icantly increased average size of LDs in T98G as well as
in HepG2 cells. These observations agreed with a sig-
nificant deficiency in surfactant phospholipids such as
phosphatidylcholine or accumulation of phosphatidic
acid under SR9009 treatment increasing LD fusion or
coalescence (Guo et al., 2008; Fei et al., 2011). In fact,
REV-ERB agonists were shown to be inhibitors of
autophagy and de novo lipogenesis, with selective activ-
ity toward malignant and benign neoplasms; the accu-
mulation of LDs may be due to an uptake and
accumulation of fatty acids (Bensaad et al., 2014) and
not to de novo synthesis of lipids as the expression of the
two key enzymes fatty acid synthase and stearoyl- CoA
desaturase 1 involved in de novo lipogenesis were
decreased after REV-ERBs agonist treatment (Sulli
et al., 2018).
Interestingly, autophagy contributes to the intracellu-
lar catabolism of lipids in hepatocytes, fibroblasts (Singh
et al., 2009), and neurons (Martinez-Vicente et al., 2010),
while the pharmacologic or genetic inhibition of
Figure 5. ROS levels in T98G cells treated with SR9009 or BOR. T98G cells were treated either with SR9009 (a, 20 mM 48 h) or BOR (b,
500 nM 24 h), and ROS levels were analyzed with the fluorescent probe 2,7-dichlorodihydrofluorescein diacetate to a final concentration
of 2 mM as described in “Materials and Methods” section. Fluorescence intensity was analyzed by flow cytometry. The results are mean 
standard error of the mean of two/three independent experiments (n¼ 3–5/group). The statistical analysis revealed a significant effect for
SR9009 (**p< .001 by t test) and for BOR (*p< .04 by t test) as compared with vehicle-treated controls. BOR¼Bortezomib.
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autophagy in hepatocytes leads to reduced rates of b oxi-
dation and marked lipid accumulation in cytosolic LDs
(Singh et al., 2009). Autophagy is an ATP-dependent
process (Meijer and Codogno, 2004), and autophagy
inhibition reduces mitochondrial b-oxidation rates
(Singh et al., 2009; Heaton et al., 2010) and energy pro-
duction. Autophagy-deficient stellate cells as shown in
hepatocytes may be unable to process LDs by acid
lipases, resulting in LD accumulation and decreased
free fatty acid availability, leading to decreased mito-
chondrial b oxidation.
Moreover, BOR treatment at low concentrations
(5 nM) was shown to cause lipid accumulation associated
with mitochondrial impairment (Guglielmi et al., 2017).
The mechanisms used for these two chemotherapeutic
agents seemed to be different concerning the redox
Figure 6. Lipid droplet (LD) levels in T98G cells treated with SR9009 or BOR. T98G cells were treated either with SR9009 (20mM, 48 h;
a to d) or BOR (500 nM, 24 h; e to f) and LD levels were analyzed by Nile Red staining. Representative microphotography of LDs observed
in vehicle (a) or SR9009-treated T98G cells (b) stained with Nile Red were visualized by confocal microscopy, further magnified in the
insets on the right. Scale bar¼ 10mm. (c) Bar graphs showing quantification of average size of LDs in SR9009-treated T98G cells. Results
revealed a higher average size of LDs in cells treated with SR9009 (*p< .003 by t test) as compared with controls. (d and f) Bar graphs
showing quantification of fluorescence intensity of LDs stained with Nile Red and analyzed by flow cytometry. In both treatments, results
showed a higher fluorescence intensity when T98G cells were treated with SR9009 (d, *p< .002 by t test) or BOR (f, *p< .025 by t test) as
compared with controls. (e) Representative histograms of fluorescence intensity of LDs were analyzed by flow cytometry in BOR-treated
cells. Data are mean standard error of the mean. The results are mean of three independent experiments (n¼ 3–5/group).
BOR¼Bortezomib.
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state because BOR induced ROS levels while
SR9009-treated cells showed decreased levels of them.
Even though the sequence of events leading to apoptosis
following proteasome inhibition by BOR is unclear, by-
products of normal cellular oxidative processes such as
ROS have been suggested as regulating the process
involved in the initiation of apoptotic signaling.
Tan et al. (1998) previously showed that an increase in
ROS generation induces cytochrome c release from mito-
chondria. Increased levels of ROS in BOR-treated cells
Figure 7. Lipid droplets (LDs) and ROS levels in HepG2 cells treated with SR9009. (a to c) Representative microphotographs of Nile Red-
stained LDs in HepG2 cells treated with the vehicle (a) or SR9009 (b, 10mM; c, 40mM). Scale bar¼ 10mm. (d) Bar graph showing quantification
of LD average size in SR9009-treated HepG2 cells that revealed a significant increase as compared with controls (***p< .0001 by ANOVA,
Bonferroni post hoc). (e) Bar graph showing quantification of LD percentage area in SR9009-treated HepG2 cells. A significant increase was
observed with 40 mM SR9009 treatment for 96 h (***p< .0001 by K-W). (f) Determination of ROS levels by flow cytometry in HepG2 cells
treated with SR9009 (5 and 40mM for 96 h). A significant reduction was observed at 40mM SR9009-treated cells as compared with vehicle and
5 and 20 mM of SR9009 (***p< .0001 by ANOVA, Bonferroni post hoc). ROS¼ reactive oxygen species.
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were also observed in colorectal (Kim, 2012) and human
H460 nonsmall cell lung cancer cells (Ling et al., 2003) as
well as in human leukemia cells (Yu et al., 2004).
Conversely, SR9009-treated cells showed decreased
ROS levels as compared with untreated cells for both
tumor cell lines. These results support the idea proposed
by Sulli et al. (2018) suggesting that excessive ROS pro-
duction is not involved in the enhanced sensitivity of
cancer cells to SR9009 treatment.
Overall, the pharmacological activation of REV-ERBs
by the pyrrole derivative SR9009 as specific agonist (Solt
et al., 2012) has been clearly shown to affect tumor cell
viability restricting abnormally activated pathways as dem-
onstrated on different tumor cell types, namely, brain, leu-
kemia, breast, colon, and melanoma (Sulli et al., 2018).
Therefore, and in agreement with these previously reported
observations, the antitumor activity of SR9009 was clearly
evidenced in T98G and HepG2 cells displaying significant
cytotoxic effects and pronounced metabolic changes.
Summary
T98G cells constitute a glioblastoma model to evaluate
the pharmacological modulation of tumor-intrinsic circa-
dian clock components as anticancer strategies. Pyrrole
derivatives (SR9009) acting as specific REV-ERBs ago-
nists (circadian clock repressors) displayed potent in vitro
activity on cancer cell metabolism and viability.
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